Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 18/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4301356 | 0.87 | FAAH (0.65) | FAAH | |
| SCHEMBL4294872 | 0.84 | FAAH (0.60) | FAAH | |
| SCHEMBL4296770 | 0.83 | FAAH (0.75) | FAAH | |
| SCHEMBL13663442 | 0.83 | FAAH (0.75) | FAAH | |
| SCHEMBL4298554 | 0.82 | FAAH (0.53) | FAAH | |
| SCHEMBL4295675 | 0.82 | FAAH (0.60) | FAAH | |
| SCHEMBL4295425 | 0.82 | FAAH (0.60) | FAAH | |
| SCHEMBL4297038 | 0.81 | FAAH (0.57) | FAAH | |
| SCHEMBL4304107 | 0.81 | FAAH (0.53) | FAAHCYP1A2CLK4TP53CYP2D6 | |
| SCHEMBL4290033 | 0.81 | FAAH (0.57) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598202-B2 | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-03 | — | — | US | disclosed |
| EP-2254415-B1 | ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-23 | — | — | EP | disclosed |
| US-20090264429-A1 | Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264429-A1 | Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase | FAAH, FAAH2, HRH2 | FAAH 1/4885CYP1A2 524/4885CLK4 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.